企業プロフィール
Milestone Pharmaceuticals Inc. 株価・ニュース・カタリスト
- ティッカー:
- MIST
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- Canada
株価パフォーマンス
1.10 USD (0.00%)
終値
最終更新: 2026年8月17日
164M USD
時価総額
株価変動の要因
As of Aug 17, 2026, MIST was little changed and closed at $1.10. No new same-company headline was identified in the current news window.
企業概要
Self-Administered Cardiac Rescue Therapy
Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions that patients can administer outside a medical setting.
CARDAMYST
CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal supraventricular tachycardia to sinus rhythm.
Atrial Fibrillation Expansion
The Phase 3 ReVeRA-301 study evaluates etripamil in atrial fibrillation with rapid ventricular rate. The program uses the same self-administered regimen approved for paroxysmal supraventricular tachycardia.
International Development
The European Medicines Agency is reviewing etripamil for paroxysmal supraventricular tachycardia under the proposed brand TACHYMIST.
今後のカタリスト
- Enrollment of the first patient in the Phase 3 ReVeRA-301 study of etripamil in atrial fibrillation with rapid ventricular rate.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。